new drug

esperion

Esperion Announces Positive Phase 2 Clinical Trial Results for ETC-1002

Esperion Therapeutics, a privately held biotechnology company in Plymouth, Monday announced positive results from a Phase 2 clinical trial for its potential cholesterol buster, ETC-1002.

WWJ Newsradio 950–03/26/2012

metabolic solutions

Metabolic Solutions Receives $1.1 Million NIH Grant

Metabolic Solutions Development Co. LLC announced it has received a $1.1 million multi-year Small Business Technology Transfer Program grant from the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health. The company will use the money to develop its drug candidate for fatty liver disease.

WWJ Newsradio 950–10/06/2011

NephRx Corp. Starts Human Trial Of Kidney Transplant Assist Drug

Kalamazoo-based NephRx Corp. announced that it has initiated a Phase I clinical trial of its lead compound NX001 and has successfully dosed the first subject in the study. NX001, a kidney growth factor peptide that […]

11/11/2010

Karmanos Cancer Center Gets New Prostate Drug

Officials at the Barbara Ann Karmanos Cancer Center in Detroit said Wednesday that they had been selected to be one of 50 sites in the United States to offer the new U.S. Food and Drug […]

09/15/2010

Follow

Get every new post delivered to your Inbox.

Join 2,498 other followers